Adding a Twist to Lateral Flow Immunoassays: A Direct Replacement of Antibodies with Helical Affibodies, from Selection to Application.

Publication date: Mar 26, 2025

Immunoreagents, most commonly antibodies, are integral components of lateral flow immunoassays. However, the use of antibodies comes with limitations, particularly relating to their reproducible production, and poor thermal and chemical stability. Here, we employ phage display to develop affibodies, a class of nonimmunoglobulin affinity proteins based on a small three-helix bundle scaffold, against SARS-CoV-2 Spike protein. Subsequently, we demonstrate the utility and viability of affibodies to directly replace antibodies in lateral flow immunoassays. In addition, we highlight several physiochemical advantages of affibodies, including their ability to withstand exposure to high temperature and humidity while maintaining superior performance compared to their antibody counterparts. Furthermore, we investigate the adsorption mechanism of affibodies to the surface of gold nanoparticle probes via a His-tag, introduced to also facilitate recombinant purification. Through molecular dynamics simulations, we elucidate the structural and physical characteristics of affibody dimers which result in high-performing detection probes when immobilized on nanoparticle surfaces. This work demonstrates that affibodies can be used as direct replacements to antibodies in immunoassays and should be further considered as alternatives owing to their improved physiochemical properties and modular design.

Open Access PDF

Concepts Keywords
Antibody Adding
Class Affibodies
Nanoparticle Antibodies
Poor Direct
Thermal Flow
Helical
High
Immunoassays
Lateral
Nanoparticle
Physiochemical
Probes
Replacement
Selection
Twist

Semantics

Type Source Name
disease IDO production
drug DRUGBANK Gold
drug DRUGBANK Montelukast
disease IDO protein
disease MESH communicable diseases
disease IDO host
disease IDO process
drug DRUGBANK Adenosine 5′-phosphosulfate
drug DRUGBANK Amino acids
disease IDO assay
drug DRUGBANK Platinum
drug DRUGBANK Human Serum Albumin
drug DRUGBANK Trypsin
pathway REACTOME Digestion
disease MESH dissociation
drug DRUGBANK L-Cysteine
disease MESH immobilization
drug DRUGBANK Tretamine
pathway REACTOME Signal amplification
disease IDO reagent
drug DRUGBANK Biotin
drug DRUGBANK Water
drug DRUGBANK Spinosad
drug DRUGBANK Histidine
drug DRUGBANK Pidolic Acid
drug DRUGBANK Activated charcoal
drug DRUGBANK L-Lysine
pathway REACTOME Translation
drug DRUGBANK Coenzyme M
drug DRUGBANK Tromethamine
drug DRUGBANK Cobalt
drug DRUGBANK Imidazole
drug DRUGBANK Urea
drug DRUGBANK Acetic acid
drug DRUGBANK Sodium acetate
drug DRUGBANK Sodium lauryl sulfate
drug DRUGBANK Dextran
drug DRUGBANK Carbonate ion
drug DRUGBANK Dimethyl sulfoxide
drug DRUGBANK Amber
drug DRUGBANK Hydrogen peroxide
drug DRUGBANK Ethionamide
drug DRUGBANK Huperzine B
disease IDO cell
drug DRUGBANK Diethylstilbestrol
drug DRUGBANK Troleandomycin
disease IDO site
drug DRUGBANK Microcrystalline cellulose
drug DRUGBANK Dopamine
drug DRUGBANK Hydrocortisone
drug DRUGBANK Ampicillin
drug DRUGBANK Silver
drug DRUGBANK Streptomycin
disease MESH Multiple Myeloma
drug DRUGBANK Trestolone

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *